Printer Friendly

Articles from M2 Pharma (November 27, 2018)

1-26 out of 26 article(s)
Title Author Type Words
Acadia Pharmaceuticals Plans to Raise USD 200m from Common Stock Offering. 246
AstraZeneca announces grant of Orphan Drug Designation by US FDA for Fasenra. 203
Australia's Actinogen Medical enrols final patient into XanADu trial. 186
BlueRock Therapeutics names new chief legal and administrative officer. 202
CheckMate -451 Study Did Not Meet Primary Endpoint of Overall, According to Bristol-Myers Squibb. Report 547
Cyclica Teams with Bayer to Drive Drug Discovery through AI-Augmented Integrated Network of Cloud-Based Technologies. 162
Eagle Pharmaceuticals Touts Positive Results of Pre-clinical Study Conducted to Evaluate Effects of Ryanodex in Acute Radiation Syndrome. Clinical report 457
Enanta Pharmaceuticals Inc achieves higher net income of USD72.0m for fiscal year 2018. 197
Johnston Resigns as Chief Financial Officer of ImmunoGen. 193
MDxHealth wins New York State approval for launch of SelectMDx test for prostate cancer. 252
Navidea Biopharmaceuticals Names Rouan to Board of Directors. 357
Novacyt's Primerdesign division signs USD3m diagnostics supply agreement with Genesis Diagnostics. 187
ORIC Pharmaceuticals names Matt Panuwat as CBO. 125
ORIC Pharmaceuticals names new chief business officer. 164
Perrigo awarded US FDA tentative approval for first to file generic Ultravate Lotion 0.05%. 142
Poxel starts PXL065 part two phase 1a studyPoxel starts PXL065 part two phase 1a study. 265
Puration and Generex Biotechnology partnership to develop and produce CBD HydroHealth high alkaline health water. 215
Rocket Pharmaceuticals and REGENXBIO partnership to develop new gene therapies for Danon Disease. 278
Rocket Pharmaceuticals expects USD50m from public offering of common stock. 177
Rocket Pharmaceuticals Plans to Raise USD 50m from Common Stock Offering. 190
SeraCare Life Sciences acquired by LGC. 203
Tactiva Therapeutics signs license agreement for the oncolytic vaccinia virus for the treatment of ovarian cancer. 212
Tele2 optimistic about EC approval of merger with T-Mobile in the Netherlands. 155
The US FDA approves first ever TRK Inhibitor Vitrakvi (larotrectinib) for advanced TRK fusion cancer. 298
Zealand Pharma's president and CEO to depart. 105
Zymeworks, BeiGene Ink License and Collaboration Agreement for Zymeworks' HER2-Targeted Therapeutic Candidates, ZW25 and ZW49, in Asia-Pacific and Research and License Agreement for Zymeworks' Azymetric and EFECT Platforms Globally. 984

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters